Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
9MW2821 vs Chemotherapy in Recurrent or Metastatic Cervical Cancer
NCT06692166Phase 3Recruiting
- Sponsor
- Mabwell
- Start
- Sep 2024
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bulumtatug fuvedotin in Cervical Cancer (CC) (2 arms), sponsored by Mabwell. Primary endpoint: Overall Survival up to 3 years. Started Sep 2024; status: recruiting.
02
Drugs
bulumtatug fuvedotin
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT06692166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06692166.